NCT00354679View on ClinicalTrials.gov

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Esophageal Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

cisplatin

DRUG

irinotecan hydrochloride

GENETIC

proteomic profiling

OTHER

diagnostic laboratory biomarker analysis

OTHER

mass spectrometry

PROCEDURE

adjuvant therapy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic conventional surgery

RADIATION

radiation therapy

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00354679 - Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter